Savara Inc. (SVRA) CEO Rob Neville on Q4 2019 Results - Earnings Call Transcript

Savara Inc. (NASDAQ:SVRA) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET

Company Participants

Anne Erickson - Vice President of Investor Relations and Corporate Communications
Rob Neville - Chief Executive Officer
Badrul Chowdhury - Chief Medical Officer
Taneli Jouhikainen - Chief Operating Officer
Dave Lowrance - Chief Financial Officer

Conference Call Participants

Josh Schimmer - Evercore ISI
Suji Jeong - Jefferies LLC

Operator

Welcome to the Savara conference call. At this time, all participants are in listen-only mode. An audio webcast of this call will be available on the Investors section of Savara’s website at savarapharma.com. This call is subject to copyright and is the property of Savara.

All recordings, reproduction or transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today’s call is being recorded.

I would now like to turn the phone over to Anne Erickson, Head of Investor Relations and Corporate Communications at Savara.

Anne Erickson

Good afternoon and thank you for joining us today. A press release reporting our fourth quarter, end of year 2019 financial results was issued earlier today, March 12, 2020, and can be found on the Investors section of our website at savarapharma.com. If you’ve not received this release or if you’d like to be added to the company’s distribution list, please e-mail me at [e-mail].

This call is also being webcast live. And approximately one hour after the call, a replay will be available on the company’s website and will remain available for the next 30 days. A telephone replay will also be available through March 19.

Please note that today’s conference call and webcast contain forward-looking statements within the meaning of federal securities laws, including statements regarding the company’s strategy, goals, product candidates, clinical studies and financing matters. Such statements are subject to significant risks